Literature DB >> 29242363

Diagnostic Accuracy of Amino Acid and FDG-PET in Differentiating Brain Metastasis Recurrence from Radionecrosis after Radiotherapy: A Systematic Review and Meta-Analysis.

H Li1, L Deng1, H X Bai2, J Sun2, Y Cao3, Y Tao3, L J States4, M D Farwell2, P Zhang5, B Xiao6, L Yang7.   

Abstract

BACKGROUND: Current studies that analyze the usefulness of amino acid and FDG-PET in distinguishing brain metastasis recurrence and radionecrosis after radiation therapy are limited by small cohort size.
PURPOSE: Our aim was to assess the diagnostic accuracy of amino acid and FDG-PET in differentiating brain metastasis recurrence from radionecrosis after radiation therapy. DATA SOURCES: Studies were retrieved from PubMed, Embase, and the Cochrane Library. STUDY SELECTION: Fifteen studies were included from the literature. Each study used PET to differentiate radiation necrosis from tumor recurrence in contrast-enhancing lesions on follow-up brain MR imaging after treating brain metastasis with radiation therapy. DATA ANALYSIS: Data were analyzed with a bivariate random-effects model. Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were pooled, and a summary receiver operating characteristic curve was fit to the data. DATA SYNTHESIS: The overall pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of PET were 0.85, 0.88, 7.0, 0.17, and 40, respectively. The area under the receiver operating characteristic curve was 0.93. On subgroup analysis of different tracers, amino acid and FDG-PET had similar diagnostic accuracy. Meta-regression analysis demonstrated that the method of quantification based on patient, lesion, or PET scan (based on lesion versus not, P = .07) contributed to the heterogeneity. LIMITATIONS: Our study was limited by small sample size, and 60% of the included studies were of retrospective design.
CONCLUSIONS: Amino acid and FDG-PET had good diagnostic accuracy in differentiating brain metastasis recurrence from radionecrosis after radiation therapy.
© 2018 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29242363     DOI: 10.3174/ajnr.A5472

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  10 in total

1.  Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors:  Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

2.  Selective Cell Size MRI Differentiates Brain Tumors from Radiation Necrosis.

Authors:  Sean P Devan; Xiaoyu Jiang; Guozhen Luo; Jingping Xie; James D Quirk; John A Engelbach; Hannah Harmsen; Eliot T McKinley; Jing Cui; Zhongliang Zu; Albert Attia; Joel R Garbow; John C Gore; Colin D McKnight; Austin N Kirschner; Junzhong Xu
Journal:  Cancer Res       Date:  2022-10-04       Impact factor: 13.312

3.  Searching practices and inclusion of unpublished studies in systematic reviews of diagnostic accuracy.

Authors:  Daniël A Korevaar; Jean-Paul Salameh; Yasaman Vali; Jérémie F Cohen; Matthew D F McInnes; René Spijker; Patrick M Bossuyt
Journal:  Res Synth Methods       Date:  2020-02-05       Impact factor: 5.273

4.  Individualized discrimination of tumor recurrence from radiation necrosis in glioma patients using an integrated radiomics-based model.

Authors:  Kai Wang; Zhen Qiao; Xiaobin Zhao; Xiaotong Li; Xin Wang; Tingfan Wu; Zhongwei Chen; Di Fan; Qian Chen; Lin Ai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-26       Impact factor: 9.236

5.  Dynamic susceptibility MR perfusion in diagnosing recurrent brain metastases after radiotherapy: A systematic review and meta-analysis.

Authors:  Robert M Kwee; Thomas C Kwee
Journal:  J Magn Reson Imaging       Date:  2019-05-31       Impact factor: 4.813

6.  Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR.

Authors:  Robert J Young; Paula Demétrio De Souza França; Giacomo Pirovano; Anna F Piotrowski; Philip J Nicklin; Christopher C Riedl; Jazmin Schwartz; Tejus A Bale; Patrick L Donabedian; Susanne Kossatz; Eva M Burnazi; Sheryl Roberts; Serge K Lyashchenko; Alexandra M Miller; Nelson S Moss; Megan Fiasconaro; Zhigang Zhang; Audrey Mauguen; Thomas Reiner; Mark P Dunphy
Journal:  Neurooncol Adv       Date:  2020-09-15

7.  [18F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis.

Authors:  Ephraim E Parent; Dhruv Patel; Jonathon A Nye; Zhuo Li; Jeffrey J Olson; David M Schuster; Mark M Goodman
Journal:  EJNMMI Res       Date:  2020-12-07       Impact factor: 3.138

Review 8.  Research progress on mechanism and imaging of temporal lobe injury induced by radiotherapy for head and neck cancer.

Authors:  Zhuangzhuang Zheng; Bin Wang; Qin Zhao; Yuyu Zhang; Jinlong Wei; Lingbin Meng; Ying Xin; Xin Jiang
Journal:  Eur Radiol       Date:  2021-07-29       Impact factor: 5.315

Review 9.  Radiation Necrosis from Stereotactic Radiosurgery-How Do We Mitigate?

Authors:  Balamurugan A Vellayappan; Tresa McGranahan; Jerome Graber; Lynne Taylor; Vyshak Venur; Richard Ellenbogen; Andrew E Sloan; Kristin J Redmond; Matthew Foote; Samuel T Chao; John H Suh; Eric L Chang; Arjun Sahgal; Simon S Lo
Journal:  Curr Treat Options Oncol       Date:  2021-06-07

Review 10.  Diagnostic Performance and Prognostic Value of PET/CT with Different Tracers for Brain Tumors: A Systematic Review of Published Meta-Analyses.

Authors:  Giorgio Treglia; Barbara Muoio; Gianluca Trevisi; Maria Vittoria Mattoli; Domenico Albano; Francesco Bertagna; Luca Giovanella
Journal:  Int J Mol Sci       Date:  2019-09-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.